Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers.
Target Price
The average target price of PEPG is 10 and suggests 561% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas